Cetyl Alcohol

Cetyl Alcohol

SCHEMBL3746332

CCCCCCCCC(CO)CCCCCC.CCCCCCCCCCCCCCCCO

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.86
ALDH1A1 P00352 3/20 0.62
HSD17B10 Q99714 1/20 0.62
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
TSHR P16473 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.57
CYP2D6 P10635 2/20 0.47
SPHK1 Q9NYA1 1/20 0.47
GMNN O75496 1/20 0.47
POLB P06746 1/20 0.47
THPO P40225 1/20 0.47
MTOR P42345 1/20 0.47
BLM P54132 1/20 0.47
KDM4E B2RXH2 1/20 0.47
TP53 P04637 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
CETP P11597 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10053855 1.00 LMNA (0.86) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL525391 1.00 LMNA (0.86) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL20983223 1.00 LMNA (0.86) LMNAALDH1A1HSD17B10MEN1KMT2A
Octyldodecanol SCHEMBL21295571 1.00 LMNA (0.86) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL22462335 1.00 LMNA (0.86) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL8970052 1.00 LMNA (0.86) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL20983220 1.00 LMNA (0.86) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL22211645 1.00 LMNA (0.86) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL22462334 1.00 LMNA (0.86) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL4844608 1.00 LMNA (0.86) LMNAALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7833995-B2 Blood flow promoters for cauda equina tissues ONO PHARMACEUTICAL CO., LTD. (JP) 2010-11-16 US disclosed
EP-2102289-A2 ENCAPSULATED COLORANTS FOR WATERBORNE COATING COMPOSITIONS SYSTEM KIT AND METHOD Akzo Nobel Paints LLC (US) 2009-09-23 EP disclosed
WO-2007115335-A2 ENCAPSULATED COLORANTS FOR WATERBORNE COATING COMPOSITIONS SYSTEM KIT AND METHOD THE GLIDDEN COMPANY (US) 2007-10-11 WO disclosed
US-20070129327-A1 Blood flow promoters for cauda equina tissues ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129327-A1 Blood flow promoters for cauda equina tissues PTGFR, PTGIS, PTGIR LMNA 1814/4885ALDH1A1 427/4885HSD17B10 1440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.